NCT07106294 Hyperspectral Imaging for Prediction of Preeclampsia
| NCT ID | NCT07106294 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Heidelberg University |
| Condition | Preeclampsia (PE) Risk |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,430 participants |
| Start Date | 2025-08-21 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,430 participants in total. It began in 2025-08-21 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Preeclampsia is a hypertensive pregnancy disorder that can quickly lead to serious, potentially life-threatening outcomes for both the mother and the fetus. Typical features of preeclampsia are by endothelial and microvascular dysfunctionsNotably, such impairments in endothelial function may precede preeclampsia diagnosis and canpersist for years postpartum. In clinical practice, however, no predictive methods have yet been established that specifically reflect endothelial dysfunction in the context of preeclampsia. Hyperspectral imaging represents a new and non-invasive imaging modality that allows contact-free visualization of peripheral microcirculatory dynamics and tissue perfusion. Despite its growing use in other medical fields, this technology has not yet been systematically studied to determine its predictive potential in preeclampsia. The HIPPA project (Systematic Evaluation of Hyperspectral Analysis for Prediction of Preeclampsia) is a prospective observational study to evaluate the applicability of hyperspectral imaging as a new tool for prediction of preeclampsia.
Eligibility Criteria
Inclusion Criteria: * singleton pregnancies * age ≥ 18 years * patient's ability to provide consent * written informed consent * women scheduled for a routine ultrasound scan in first or second trimester Exclusion Criteria: * lack of consent * language barrier * severe fetal chromosomal/genetic/structural anomalies known at study enrollment * smoking in the last two hours before measurement * diagnosis of preeclampsia at study enrollment
Contact & Investigator
Dr. med. Alexandra von Au
PRINCIPAL INVESTIGATOR
University Heidelberg
Frequently Asked Questions
Who can join the NCT07106294 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Preeclampsia (PE) Risk. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07106294 currently recruiting?
Yes, NCT07106294 is actively recruiting participants. Contact the research team at anna.scholz@med.uni-heidelberg.de for enrollment information.
Where is the NCT07106294 trial being conducted?
This trial is being conducted at Heidelberg, Germany.
Who is sponsoring the NCT07106294 clinical trial?
NCT07106294 is sponsored by Heidelberg University. The principal investigator is Dr. med. Alexandra von Au at University Heidelberg. The trial plans to enroll 1,430 participants.